| Transplantation in patients with lower-risk MDS: a prospective phase 2 trial based on donor availability |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Updates in low/intermediate-risk MDS |
|
The Hematology, ASH Education Program |
Myelodysplastic Syndromes (MDS) |
| Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor risk MDS/AML |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Sequential versus standard conditioning in untreated MDS patients with blasts undergoing allogeneic HSCT |
|
Bone Marrow Transplant |
Myelodysplastic Syndromes (MDS) |
| Infections in lower-risk myelodysplastic syndromes - prevalence and risk factors: a report from the European MDS Registry |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
| Optimal timing of allogeneic hematopoietic stem cell transplant in MDS |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| New Approvals in Low- and Intermediate-Risk Myelodysplastic Syndromes |
|
American Society of Clinical Oncology Educational Book |
Myelodysplastic Syndromes (MDS) |
| Allogeneic Stem Cell Transplant for Myelofibrosis and Myelodysplastic Syndromes: A Contemporary Review |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| Germline and somatic genetic landscape of pediatric myelodysplastic syndromes |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
